SL
KRYS icon

Salomon & Ludwin’s Krystal Biotech KRYS Stock Holding History

Salomon & Ludwin’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.3K Buy
227
+26
+13% +$7.77K 0.01% 318
2026
Q1 		$52.5K Buy
201
+18
+10% +$4.79K ﹤0.01% 462
2025
Q4 		$44.8K Buy
183
+1
+0.5% +$210 ﹤0.01% 442
2025
Q3 		$33.4K Buy
+182
New +$27.2K ﹤0.01% 523

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Salomon & Ludwin's KRYS Position: Q2 2026 in Review

Salomon & Ludwin increased its Krystal Biotech (KRYS) stake by 13% in Q2 2026, buying an estimated $7.77K and bringing the position to 227 shares worth $84.3K. The position accounts for 0.01% of the portfolio, ranked #318.

Salomon & Ludwin first reported a position in KRYS in Q3 2025 and has held it in 4 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Salomon & Ludwin held 227 shares of Krystal Biotech worth $84.3K as of Q2 2026.
  • Salomon & Ludwin bought 26 Krystal Biotech shares in Q2 2026, an estimated $7.77K.
  • Krystal Biotech made up 0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #318 holding.
  • Salomon & Ludwin first reported a position in Krystal Biotech in Q3 2025 and has held it in 4 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.